Some embodiments are directed to a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, to be used as a drug for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer in association with a eukaryotic cell for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to the use of a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, for manufacturing a drug for the treatment of tissue lesions. Some other embodiments can be used in particular in the veterinary and pharmaceutical fields.

Some embodiments are directed to a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, to be used as a drug for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer in association with a eukaryotic cell for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to the use of a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, for manufacturing a drug for the treatment of tissue lesions. Some other embodiments can be used in particular in the veterinary and pharmaceutical fields.

Disclosed is a cell structure comprising: a fragmented extracellular matrix component; and cells, wherein the cell structure comprises an intercellular vascular network, and the cells comprise at least adipocytes and vascular endothelial cells.

Disclosed is a cell structure comprising: a fragmented extracellular matrix component; and cells, wherein the cell structure comprises an intercellular vascular network, and the cells comprise at least adipocytes and vascular endothelial cells.

Therapeutic chondrisome compositions and related methods are described.

Therapeutic chondrisome compositions and related methods are described.

Provided herein are, inter alia, methods, compositions, and kits for producing adipocyte populations such as beige adipocyte populations. Also included are methods and compositions for increasing the level of adipocyte populations (e.g., beige adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.

Provided herein are, inter alia, methods, compositions, and kits for producing adipocyte populations such as beige adipocyte populations. Also included are methods and compositions for increasing the level of adipocyte populations (e.g., beige adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.

Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.

Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.